Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 22INDUSTRY 4

Study Type

Interventional 120Observational 4Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1

Conditions

Carcinoma, Hepatocellular 3Thyroid Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Carcinoma 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × lenvatinib × Clear all
NCT04763408 2024-07-18

STELLAR

Eisai Inc.

Completed
335 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Completed
412 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

NCT03663114 2021-01-22

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Completed
713 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02430714 2020-01-09

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Eisai Inc.

Completed
629 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡